VIVELLE by Novartis is characteristics. First approved in 2000.
Drug data last refreshed 22h ago · AI intelligence enriched 6d ago
VIVELLE is a transdermal estradiol film (extended-release formulation) approved in 2000 by Novartis. The product delivers estrogen systemically across the skin, bypassing first-pass metabolism. It is indicated for hormone replacement therapy and menopausal symptom management in eligible patients.
Product faces lifecycle transition with moderate competitive pressure (30/100), indicating defensive positioning and potential team restructuring as exclusivity erodes.
characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
VIVELLE offers limited career growth opportunities given zero linked job postings and approaching LOE status. Roles available are primarily defensive commercial positions focused on market maintenance and managed decline rather than expansion.
Worked on VIVELLE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.